Search Submit Your Manuscript

Become A Member

  1. Home
  2. July 2023
  3. 26. Hyponatremia Associated with Pregabalin
Article Image
Admin

26. Hyponatremia Associated with Pregabalin

Shafiq ur Rehman Cheema1, Ambreen Tauseef2, Manal Fatima2, Marium Danish Iqbal2, Rabia Rehman1 and Sidra Shafiq Cheema2

ABSTRACT

Objective: To assess if hyponatremia is associated with pregabalin. Pregabalin, an analog of the neurotransmitter γ-aminobutyric acid, possesses analgesic, anticonvulsant, and anxiolytic properties.

Study Design: A prospective randomized interventional trial study

Place and Duration of Study: This study was conducted at the Jinnah Hospital dialysis center from 01st January 2021 to 31st December 2021.

Materials and Methods: All the patients with hyponatremia & taking pregabalin were included in the study. Although hyponatremia (when serum sodium level below 135 mmol/L) is the most common abnormality of electrolytes observed in hospitalized patients, it is typically associated with certain drugs such as diuretics, antidepressants, and antiepileptic medications. Notably, hyponatremia as a side effect of pregabalin has not been reported due to its relatively recent introduction. However, we present a few clinical scenarios where it is highly probable that hyponatremia was associated with pregabalin.

Results: Out of 60 patients with hyponatremia, ten were found to be taking pregabalin. Three out of 10 (30%) cases of hyponatremia were found to be associated with pregabalin. These case scenarios are discussed in detail in the main body of this study.

Conclusion: While hyponatremia is an infrequent occurrence, it is a potential side effect of pregabalin. Therefore, caution should be exercised when prescribing pregabalin to patients who are at a higher risk of developing hyponatremia

Key Words: Pregabalin, hyponatremia, electrolyte disorders.

Citation of article: Shafiq ur rehman Cheema, Tauseef A, Fatima M, Iqbal MD, Rehman R, Cheema SS. Hyponatremia Associated with Pregabalin. Med Forum 2023;34(7):112-115. doi:10.60110/medforum.340726.